Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nimotuzumab in Adjuvant HNSCC
NCT00957086Phase 3Active, not recruiting
- Sponsor
- National Cancer Centre Singapore
- Start
- Aug 2009
- Primary completion
- Jan 2025
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 13
01
Overview
A Phase 3 trial of nimotuzumab in head and neck squamous cell carcinoma (HNSCC), sponsored by National Cancer Centre Singapore. Started Aug 2009; status: active, not recruiting.
02
Drugs
nimotuzumab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT00957086.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00957086.